Introduction {#sec1}
============

Morphan (2-azabicyclo\[3.3.1\]nonane) derivatives are becoming more and more important in medicine^[@ref1],[@ref2]^ and are a common structural motif in many biologically active natural products and pharmacologically active molecules, such as the immunosuppressant FR9014834,^[@ref3]^ daphniphyllum alkaloids (cytotoxic agents),^[@ref4]^ opioid agonists (e.g., compound **A**),^[@ref5]^ opioid receptor antagonists (e.g., morphine,^[@ref6]^ compound **B**,^[@ref7]^ naloxone,^[@ref8]^ naltrexone,^[@ref9]^ TENA,^[@ref10]^ GNTI,^[@ref11]^ ANTI,^[@ref12]^ BNTI,^[@ref13]^ and C-CAM^[@ref14]^), and madangamines^[@ref15]^ ([Figure [1](#fig1){ref-type="fig"}](#fig1){ref-type="fig"}).^[@ref16]^ Morphan derivatives have been studied based on their broad spectrum of biological activities. Although many methods have been developed for the synthesis of morphan derivatives by organic or pharmaceutical chemists for many years,^[@ref17]−[@ref21]^ these approaches usually require metal catalysts under strict anhydrous conditions or multistep syntheses. Consequently, it is desirable and important to develop concise, highly regioselective, and environmentally friendly methods for building up a highly substituted morphan derivative library.

![Biologically active morphans and targeted compounds.](ao-2017-01493j_0001){#fig1}

Quinone monoketals can be easily obtained from phenols in a single step^[@ref22]^ and are widely used for the synthesis of various structurally complex molecules.^[@ref23],[@ref24]^ Though quinone monoketals contain two unsaturated C=C bonds, they usually undergo 1,4-nucleophilic addition.^[@ref25],[@ref26]^ Their reaction via double Michael addition is very seldom.^[@ref27]^

Cyclic 1,1-enediamines (EDAMs) are a fascinating and versatile building block^[@ref28]^ that is widely used to synthesize various fused heterocyclic compounds including quinolones,^[@ref29]^ isoquinolin-1-imines,^[@ref30]^ indoles,^[@ref31]^ indolin-2-ones,^[@ref32]^ isocoumarins,^[@ref33]^ pyridines,^[@ref34]^ and pyrroles.^[@ref35]^ Many of these compounds have a wide range of biological activities, such as antitumor,^[@ref36]^ herbicide, pesticide,^[@ref37]^ antianxiety,^[@ref38]^ antileishmanial,^[@ref39]^ and antibacterial.^[@ref40]^ However, acyclic EDAMs have not been considered for many years. Seldom literature reports have shown that EDAMs serve as bisnucleophiles (α-carbon and N as nucleophilic sites) and react with biselectrophiles to produce fused heterocyclic compounds.^[@ref41]^ To date, to the best of our knowledge, incorporation of the two nucleophilic sites (α-C and N) through the Michael and hetero-Michael addition of EDAMs to form bridged-ring frame compounds has not been reported.

Our group recently obtained the bridged-ring frame morphans with an immunosuppressive activity based on cyclic EDAM building blocks.^[@cit42a]^ To get molecularly diverse morphans and further investigate more active immunosuppressants,^[@cit42b]^ we designed and synthesized novel target compounds morphans by the Michael/hetero-Michael addition reaction of EDAMs through the two reaction sites (α-C and N).

Results and Discussion {#sec2}
======================

Here, we report a novel synthesis method to produce morphan derivatives **3** and **4** by refluxing the mixture of quinone monoketals **1** and EDAMs **2** in ethanol or 1,4-dioxane, promoted by cesium carbonate ([Scheme [1](#sch1){ref-type="scheme"}](#sch1){ref-type="scheme"}). The target compounds were obtained in good yields (58--90%).

![Strategy for the Michael/Hetero-Michael Addition Synthesis of Morphans **3** and **4**](ao-2017-01493j_0004){#sch1}

First, we evaluated the Michael/hetero-Michael addition reaction of quinone monoketals **1** and EDAMs **2**. The mixture (**1a**/**2a** = 1.1:1) was treated under various conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 1--20). The results demonstrated that the reaction could not proceed at reflux in 1,4-dioxane under without-additive conditions ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entry 1). Et~3~N and K~2~CO~3~ were selected as promoters to test the reaction under different solvents (ethanol, acetonitrile, 1,4-dioxane, and toluene) and reflux conditions. The result is still negative ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 2--9). Then, Cs~2~CO~3~ (2.0 equiv) was charged into the different solvents and refluxed for 6 h ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 10--14). As a result, with ethanol as the solvent, the reaction can proceed smoothly to give the target product **3a** in a 90% yield. A stronger alkali, *t*-BuOK, was used in aprotic solvents (acetonitrile and 1,4-dioxane) and protic solvents (*t*-BuOH). The results showed that the reaction becomes more complex and cannot achieve a positive result as the alkaline is too strong ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 15--17). Other organic alkalis including *N*,*N*-diisopropylethylamine (DIPEA), 1,8-diazabicyclo\[5.4.0\]-7-undecene (DBU), and 1,4-diazabicyclo\[2.2.2\]octane (DABCO) could not promote the reaction smoothly even under the optimal solvent ethanol ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 18--20). The results demonstrate that the optimal reaction conditions for the synthesis of morphan derivatives were ethanol or 1,4-dioxane as the solvent and Cs~2~CO~3~ as the promoter under reflux for 6 h in a 89--90% yield ([Table [1](#tbl1){ref-type="other"}](#tbl1){ref-type="other"}, entries 10 vs 13).

###### Optimized Conditions for the Synthesis of **3a**[a](#t1fn1){ref-type="table-fn"}

![](ao-2017-01493j_0006){#GRAPHIC-d7e412-autogenerated}

  entry   solvent           base                         *T* (°C)     time (h)   yield[b](#t1fn2){ref-type="table-fn"} (%)
  ------- ----------------- ---------------------------- ------------ ---------- -------------------------------------------
  1       1,4-dioxane       −                            reflux       12         n.r.
  2       EtOH              Et~3~N                       reflux       12         n.r.
  3       acetonitrile      Et~3~N                       reflux       12         n.r.
  4       1,4-dioxane       Et~3~N                       reflux       12         n.r.
  5       toluene           Et~3~N                       reflux       12         n.r.
  6       acetone           K~2~CO~3~                    reflux       12         n.r.
  7       EtOH              K~2~CO~3~                    reflux       12         n.r.
  8       THF               K~2~CO~3~                    reflux       12         n.r.
  9       1,4-dioxane       K~2~CO~3~                    reflux       12         n.r.
  10      **EtOH**          **Cs**~**2**~**CO**~**3**~   **reflux**   **6**      **90**
  11      acetonitrile      Cs~2~CO~3~                   reflux       6          78
  12      THF               Cs~2~CO~3~                   reflux       6          n.r.
  13      **1,4-dioxane**   **Cs**~**2**~**CO**~**3**~   **reflux**   **6**      **89**
  14      toluene           Cs~2~CO~3~                   reflux       6          n.r.
  15      acetonitrile      *t*-BuOK                     reflux       6          complex
  16      1,4-dioxane       *t*-BuOK                     reflux       6          complex
  17      *t*-BuOH          *t*-BuOK                     reflux       6          complex
  18      EtOH              DIPEA                        reflux       12         n.r.
  19      EtOH              DBU                          reflux       12         n.r.
  20      EtOH              DABCO                        reflux       12         n.r.

Reaction conditions: **1a** (1.1 mmol), **2a** (1.0 mmol), promoter (2.0 mmol), and solvent (15 mL).

Isolated yield based on EDAM **2a** (n.r. = no reaction).

Encouraged by this result, we explored the scope and limitations of the double Michael reactions involving different quinone monoketals **1** with various EDAMs **2** ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **3a--3c′**) in ethanol. The results showed that the electron-withdrawing group (F and Cl)-substituted *N*-benzyl EDAM can achieve higher yield than the electron-donating group (Me and MeO) EDAM ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **3a** vs **3c**; **3f** vs **3h**). The *N*-phenyl-ethyl EDAM follows the same rule. Longer chain EDAMs usually produce the target compounds in lower yields ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **3b** vs **3d**; **3k** vs **3l**; and **3n** vs **3p**). In addition, sterically hindered quinone monoketals can greatly decrease the yields ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}, **3s--3x**).

###### Michael/Hetero-Michael Addition for the Synthesis of Morphan Derivatives **3**[a](#t2fn1){ref-type="table-fn"}^,^[b](#t2fn2){ref-type="table-fn"}

![](ao-2017-01493j_0007){#gr6}

Reagents and conditions: **1** (1.1 mmol), **2** (1.0 mmol), Cs~2~CO~3~ (2.0 mmol), and EtOH (15.0 mL).

Isolated yield based on **2**.

It must be noted that the Michael/hetero-Michael addition reaction has very high regioselectivity and diastereoselectivity. As a result, only the target product **3** was obtained in the form of compounds **3a--3c′** (no diastereoisomers of **3a--3c′** were detected) ([Table [2](#tbl2){ref-type="other"}](#tbl2){ref-type="other"}).

To further explore the sterically hindered EDAMs, N,N-bis-substituted EDAMs **2** have been used as substrates to react with quinone monoketals **1a** in EtOH ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 1--2). As a result, we can get only moderate yields (76--80%). As 1,4-dioxane replaces EtOH as the solvent under the same conditions ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 3--4), we find that the reaction can get higher yields (80--88%). We believe that the sterically hindered EDAMs make the reaction difficult at lower temperature (at reflux in EtOH) compared with at higher temperature (at reflux in 1,4-dioxane). Consequently, different sterically hindered N,N-bis-substituted EDAMs **2** are used as substrates to react with various quinone monoketals in 1,4-dioxane for the synthesis of **4a--4o** ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 3--17). Generally, EDAMs with electron-withdrawing groups (F and Cl) often can obtain higher yields than electron-donating group EDAMs ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 3 vs 4; 10 vs 13--14). Longer chain EDAMs get the target compounds in lower yields ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 13 vs 15). The mixture of sterically hindered quinone monoketals (**1e** and **1f**) and EDAMs **2** was refluxed in ethanol under the same conditions ([Table [3](#tbl3){ref-type="other"}](#tbl3){ref-type="other"}, entries 18--19). The results demonstrated that the steric hindrance effects on quinone monoketals **1** cannot make the reaction proceed smoothly.

###### Michael/Hetero-Michael Addition for the Synthesis of Morphan Derivatives **4**[a](#t3fn1){ref-type="table-fn"}^,^[b](#t3fn2){ref-type="table-fn"}

![](ao-2017-01493j_0008){#GRAPHIC-d7e1125-autogenerated}

  entry   **1**    *n*   R             R^1^   R^2^   R^3^   R′              **4**                                yield[b](#t3fn2){ref-type="table-fn"} \[%\]
  ------- -------- ----- ------------- ------ ------ ------ --------------- ------------------------------------ ---------------------------------------------
  1       **1a**   1     Me            OMe    H      H      4-FC~6~H~4~     **4a**                               80[c](#t3fn3){ref-type="table-fn"}
  2       **1a**   1     Me            OMe    H      H      4-MeOC~6~H~4~   **4b**                               76[c](#t3fn3){ref-type="table-fn"}
  3       **1a**   1     Me            OMe    H      H      4-FC~6~H~4~     **4a**                               88[d](#t3fn4){ref-type="table-fn"}
  4       **1a**   1     Me            OMe    H      H      4-MeOC~6~H~4~   **4b**                               80[d](#t3fn4){ref-type="table-fn"}
  5       **1a**   1     Me            OMe    H      H      2,4-FC~6~H~3~   **4c**                               89[d](#t3fn4){ref-type="table-fn"}
  6       **1a**   1     Me            OMe    H      H      3,4-FC~6~H~3~   **4d**                               88[d](#t3fn4){ref-type="table-fn"}
  7       **1a**   2     Me            OMe    H      H      4-FC~6~H~4~     **4e**                               88[d](#t3fn4){ref-type="table-fn"}
  8       **1a**   2     Me            OMe    H      H      3-FC~6~H~4~     **4f**                               84[d](#t3fn4){ref-type="table-fn"}
  9       **1a**   2     Me            OMe    H      H      2-FC~6~H~4~     **4g**                               86[d](#t3fn4){ref-type="table-fn"}
  10      **1a**   2     Me            OMe    H      H      4-ClC~6~H~4~    **4h**                               83[d](#t3fn4){ref-type="table-fn"}
  11      **1a**   2     Me            OMe    H      H      3-ClC~6~H~4~    **4i**                               83[d](#t3fn4){ref-type="table-fn"}
  12      **1a**   2     Me            OMe    H      H      2-ClC~6~H~4~    **4j**                               81[d](#t3fn4){ref-type="table-fn"}
  13      **1a**   2     Me            OMe    H      H      C~6~H~5~        **4k**                               78[d](#t3fn4){ref-type="table-fn"}
  14      **1a**   2     Me            OMe    H      H      4-MeC~6~H~4~    **4l**                               75[d](#t3fn4){ref-type="table-fn"}
  15      **1a**   3     Me            OMe    H      H      C~6~H~5~        **4m**                               71[d](#t3fn4){ref-type="table-fn"}
  16      **1b**   1     Et            OEt    H      H      C~6~H~5~        **4n**                               65[d](#t3fn4){ref-type="table-fn"}
  17      **1c**   1     CH~2~CH~2~O   H      H      H      **4o**          78[d](#t3fn4){ref-type="table-fn"}   
  18      **1e**   1     Me            OMe    Me     H      C~6~H~5~        **4p**                               n.r.[d](#t3fn4){ref-type="table-fn"}
  19      **1f**   2     Me            OMe    H      Me     C~6~H~5~        **4q**                               n.r.[d](#t3fn4){ref-type="table-fn"}

Reaction conditions: **1** (1.1 mmol), **2** (1.0 mmol), and Cs~2~CO~3~ (2.0 mmol).

Isolated yield based on **2**.

EtOH (15.0 mL).

1,4-Dioxane (15.0 mL).

To achieve the molecular diversity of the products, *N*,*O*-acetal (**5a**) and *N*,*S*-acetal (**5b**),^[@ref43]^ which have different structures, were applied as substrates to react with quinone monoketals **1a--1b** to synthesize the products **6a--6c** in good to excellent yields (71--85%) ([Table [4](#tbl4){ref-type="other"}](#tbl4){ref-type="other"}).

###### Michael/Hetero-Michael Addition for the Synthesis of Morphan Derivatives **6**[a](#t4fn1){ref-type="table-fn"}^,^[b](#t4fn2){ref-type="table-fn"}

![](ao-2017-01493j_0009){#gr7}

Reagents and conditions: **1** (1.1 mmol), **5** (1.0 mmol), Cs~2~CO~3~ (2.0 mmol), and 1,4-dioxane (15.0 mL).

Isolated yield based on **5**.

To confirm the structure of the morphan derivatives, **3b**, **3e**, **3u**, and **4a** were selected as the representative compounds and were characterized by X-ray crystallography, as shown in [Figure [2](#fig2){ref-type="fig"}](#fig2){ref-type="fig"} (CCDC 1546771 and CCDC 1546772) and [Figure [3](#fig3){ref-type="fig"}](#fig3){ref-type="fig"} (CCDC 1578670 and CCDC 1546773) (see the [Supporting Information](http://pubs.acs.org/doi/suppl/10.1021/acsomega.7b01493/suppl_file/ao7b01493_si_001.pdf)).

![ORTEP diagrams of **3b** (left) and **3e** (right); ellipsoids are drawn at the 30% probability level.](ao-2017-01493j_0002){#fig2}

![ORTEP diagrams of **3u** (left) and **4a** (right); ellipsoids are drawn at the 30% probability level.](ao-2017-01493j_0003){#fig3}

A proposed mechanism of the base-promoted Michael/hetero-Michael addition reaction is shown in [Scheme [2](#sch2){ref-type="scheme"}](#sch2){ref-type="scheme"}. Initially, the quinone monoketals **1** react with EDAMs **2** via Michael addition to form the intermediate **7**. Then, intermediate compound **8** is obtained from intermediate **7** by imine--enamine tautomerization. Finally, intermediate **8** is followed by intramolecular hetero-Michael addition to produce compounds **3--4**.

![Mechanism Hypotheses for the Synthesis of Target Compounds **3--4**](ao-2017-01493j_0005){#sch2}

Conclusions {#sec3}
===========

We developed a procedure for the simple synthesis of a variety of potentially biologically active morphan derivatives based on the Michael/hetero-Michael addition reaction. Accordingly, a molecularly diverse morphan library was rapidly constructed in one-pot in good yields by simply refluxing a reaction mixture of quinone monoketals and EDAMs in an environmentally friendly solvent (ethanol) or 1,4-dioxane, promoted by Cs~2~CO~3~.

Experimental Section {#sec4}
====================

General Methods {#sec4-1}
---------------

All compounds were fully characterized by spectroscopic data. NMR spectra were recorded on a Bruker DRX300, DRX400, or DRX500, chemical shifts (δ) are expressed in ppm, *J* values are given in Hz, and deuterated DMSO-*d*~6~ or CDCl~3~ was used as the solvent. IR spectra were recorded on a FT-IR Thermo Nicolet Avatar 360 using a KBr pellet. The reactions were monitored by thin-layer chromatography (TLC) using silica gel GF~254~. The melting points were determined on an XT-4A melting point apparatus and are uncorrected. High-resolution mass spectrometry (HRMS) was performed on an Agilent LC/Msd TOF instrument. X-ray diffraction was obtained by APEX DUO.

All chemicals and solvents were used as received without further purification unless otherwise stated. All chemicals were purchased from Adamas-beta. Column chromatography was performed on silica gel (Qingdao, 200--300 mesh).

Compounds **1** were prepared according to the literature.^[@ref44],[@ref45]^ Compounds **2** were prepared according to the literature.^[@ref46]^

General Procedure for the Synthesis of Compounds **3** {#sec4-2}
------------------------------------------------------

Quinone monoketals **1** (1.1 mmol), EDAMs **2** (1.0 mmol), Cs~2~CO~3~ (2.0 mmol), and ethanol (15 mL) were charged into a 25 mL round-bottom flask. The mixture was kept at reflux for about 6 h and monitored by TLC until the quinone monoketal **1** substrate was completely consumed. After the reaction was completed, the reaction system was cooled to room temperature. The reaction mixture was poured into 25 mL of water and 50 mL of ethyl acetate for extraction and separation. Then, the crude product was concentrated by distillation under reduced pressure, purified by column chromatography (petroleum ether/ethyl acetate = 1:2), and produced a series of compounds **3** in a 58--90% yield.

### (1*R*,5*R*)-3-((4-Fluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3a**) {#sec4-2-1}

Yellow solid; mp 130.3 °C; IR (KBr): 3424, 1720, 1619, 1563, 1381, 1223, 1057, 755 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.19--2.22 (m, 1H, COCH~2~), 2.35--2.38 (m, 1H, COCH~2~CHN), 2.67--2.71 (m, 1H, COCH~2~), 2.81--2.85 (m, 1H, COCH~2~CHN), 3.12 (s, 3H, OCH~3~), 3.34 (s, 3H, OCH~3~), 3.70--3.74 (m, 1H, CH), 3.90--3.94 (m, 1H, CHN), 4.48--4.51 (m, 2H, CH~2~N), 7.20--7.32 (m, 4H, ArH), 8.08 (br, 1H, NH), 10.97 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.4, 41.4, 43.8, 46.2, 48.6, 48.9, 50.6, 96.4, 107.3, 115.9 (d, *J* = 21.3 Hz), 129.5 (d, *J* = 7.5 Hz), 133.3, 153.7, 162.0 (d, *J* = 241.3 Hz), 208.3; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −115.2; HRMS (EI^+^): *m*/*z* calcd for C~17~H~21~FN~3~O~5~ \[M + H\]^+^, 366.1460; found, 366.1460.

### (1*R*,5*R*)-3-(Benzylamino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3b**) {#sec4-2-2}

Yellow solid; mp 256.5--257.5 °C; IR (KBr): 3423, 3254, 1720, 1621, 1562, 1386, 1267, 1053, 741 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.22--2.25 (m, 1H, COCH~2~), 2.39--2.41 (m, 1H, COCH~2~CHN), 2.50--2.51 (m, 1H, COCH~2~), 2.69--2.70 (m, 1H, COCH~2~CHN), 3.14 (s, 3H, OCH~3~), 3.35 (s, 3H, OCH~3~), 3.74--3.76 (m, 1H, CH), 3.92--3.96 (m, 1H, CHN), 4.52--4.57 (m, 2H, CH~2~N), 7.26--7.41 (m, 5H, ArH), 8.13 (br, 1H, NH~2~), 11.01 (br, 1H, NH~2~); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.4, 41.4, 44.5, 46.2, 48.7, 48.9, 50.7, 96.5, 107.3, 127.4, 127.9, 129.1, 137.0, 153.7, 208.3; HRMS (EI^+^): *m*/*z* calcd for C~17~H~22~N~3~O~5~ \[M + H\]^+^, 348.1554; found, 348.1556.

### (1*R*,5*R*)-9,9-Dimethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3c**) {#sec4-2-3}

Yellow solid; mp 182.6 °C; IR (KBr): 3440, 1720, 1621, 1561, 1384, 1252, 1027, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.24--2.27 (m, 1H, COCH~2~), 2.36--2.39 (m, 1H, COCH~2~CHN), 2.68--2.72 (m, 1H, COCH~2~), 2.83--2.87 (m, 1H, COCH~2~CHN), 3.15 (s, 3H, OCH~3~), 3.74 (s, 3H, OCH~3~), 3.73--3.74 (m, 1H, CH), 3.98--4.02 (m, 1H, CHN), 6.94--6.96 (m, 2H, ArH), 7.22--7.24 (m, 2H, ArH), 8.09 (br, 1H, NH), 10.92 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.4, 41.4, 44.2, 46.2, 48.7, 48.9, 50.7, 55.6, 96.5, 107.3, 114.6, 128.8, 129.0, 153.5, 159.2, 208.3; HRMS (EI^+^): *m*/*z* calcd for C~18~H~24~N~3~O~6~ \[M + H\]^+^, 378.1660; found, 378.1659.

### (1*R*,5*R*)-9,9-Dimethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3d**) {#sec4-2-4}

White solid; mp 186.4 °C; IR (KBr): 3430, 1721, 1621, 1564, 1345, 1287, 1034, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.27--2.36 (m, 2H, COCH~2~, COCH~2~CHN), 2.66--2.67 (m, 1H, COCH~2~), 2.82--2.87 (m, 3H, COCH~2~CHN, CH~2~Ar), 3.16 (s, 3H, OCH~3~), 3.34 (s, 3H, OCH~3~), 3.44--3.46 (m, 2H, CH~2~N), 3.70--3.71 (m, 1H, CH), 3.92--3.96 (m, 1H, CHN), 7.23--7.33 (m, 5H, ArH), 8.03 (br, 1H, NH), 10.69 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 34.8, 37.7, 41.9, 43.2, 46.7, 49.1, 49.3, 51.1, 96.9, 107.5, 127.4, 129.3, 129.7, 139.2, 153.9, 208.7; HRMS (EI^+^): *m*/*z* calcd for C~18~H~24~N~3~O~5~ \[M + H\]^+^, 326.1710; found, 326.1713.

### (1*R*,5*R*)-3-((3-Chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3e**) {#sec4-2-5}

White solid; mp 202.8--203.3 °C; IR (KBr): 3423, 1721, 1621, 1570, 1344, 1288, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.28--2.37 (m, 2H, COCH~2~, COCH~2~CHN), 2.67--2.71 (m, 1H, COCH~2~), 2.83--2.89 (m, 3H, COCH~2~ CHN, CH~2~Ar), 3.17 (s, 3H, OCH~3~), 3.34 (s, 3H, OCH~3~), 3.44--3.49 (m, 2H, CH~2~N), 3.69--3.73 (m, 1H, CH), 3.94--3.98 (m, 1H, CHN), 7.22--7.24 (m, 1H, ArH), 7.29--7.36 (m, 2H, ArH), 7.37--7.41 (m, 1H, ArH), 8.06 (br, 1H, NH), 10.70 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 33.9, 37.3, 41.4, 42.3, 46.2, 48.7, 48.9, 50.6, 96.4, 107.1, 127.0, 128.1, 129.2, 130.7, 133.5, 141.3, 153.5, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~18~H~23~ClN~3~O~5~ \[M + H\]^+^, 396.1321; found, 396.1323.

### (1*R*,5*R*)-9,9-Diethoxy-3-((4-fluorobenzyl)amino)-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3f**) {#sec4-2-6}

Yellow liquid; mp 130.0 °C; IR (KBr): 3416, 3258, 1719, 1619, 1563, 1344, 1057, 755 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.02--1.04 (m, 3H, CH~3~CH~2~O), 1.18--1.20 (m, 3H, CH~3~CH~2~O), 2.40--2.44 (m, 1H, COCH~2~), 2.56--2.57 (m, 2H, COCH~2~, COCH~2~CHN), 2.71--2.75 (m, 1H, COCH~2~CHN), 3.33--3.43 (m, 2H, CH~2~O), 3.52--3.59 (m, 2H, CH~2~O), 3.72--3.76 (m, 1H, CH), 4.04--4.08 (m, 1H, CHN), 4.33--4.44 (m, 2H, CH~2~N), 6.89--6.92 (m, 2H, ArH), 7.06--7.09 (m, 2H, ArH), 8.32 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 10.3, 10.4, 33.5, 36.3, 39.8, 41.0, 46.8, 51.9, 51.9, 91.2, 104.3, 111.0 (d, *J* = 21.3 Hz), 124.1 (d, *J* = 21.3 Hz), 126.5, 149.0, 158.6 (d, *J* = 245.0 Hz), 203.8; HRMS (EI^+^): *m*/*z* calcd for C~19~H~25~FN~3~O~5~ \[M + H\]^+^, 394.1773; found, 394.1773.

### (1*R*,5*R*)-3-(Benzylamino)-9,9-diethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3g**) {#sec4-2-7}

White solid; mp 172.0 °C; IR (KBr): 3417, 3250, 1720, 1616, 1567, 1348, 1092, 757 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.06--1.09 (m, 3H, CH~3~CH~2~O), 1.20--1.23 (m, 3H, CH~3~CH~2~O), 2.20--2.23 (m, 1H, COCH~2~), 2.36--2.39 (m, H, COCH~2~CHN), 2.68--2.72 (m, 1H, COCH~2~), 2.82--2.86 (m, 1H, COCH~2~CHN), 3.33--3.37 (m, 2H, CH~3~CH~2~), 3.61--3.71 (m, 2H, CH~3~CH~2~), 3.71--3.73 (m, 1H, CH), 3.91 (s, 1H, CHN), 4.52--4.55 (m, 2H, CH~2~N), 7.23--7.25 (m, 2H, ArH), 7.28--7.31 (m, 1H, ArH), 7.35--7.38 (m, 2H, ArH), 8.06 (br, 1H, NH), 11.035 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.5, 15.5, 38.2, 41.5, 44.3, 46.3, 51.4, 56.5, 56.7, 96.2, 107.5, 127.2, 127.9, 129.0, 137.2, 153.8, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~19~H~26~N~3~O~5~ \[M + H\]^+^, 376.1867; found, 376.1872.

### (1*R*,5*R*)-9,9-Diethoxy-3-((4-methoxybenzyl)amino)-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3h**) {#sec4-2-8}

Yellow solid; mp 116.3 °C; IR (KBr): 3416, 3251, 1719, 1614, 1561, 1345, 1056, 755 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.05--1.08 (m, 3H, CH~3~CH~2~O), 1.20--1.23 (m, 3H, CH~3~CH~2~O), 2.22--2.35 (m, 1H, COCH~2~), 2.36--2.39 (m, 1H, COCH~2~CHN), 2.68--2.72 (m, 1H, COCH~2~), 2.83--2.87 (m, 1H, COCH~2~CHN), 3.33--3.38 (m, 1H, CH~3~CH~2~O), 3.45--3.48 (m, 1H, CH~3~CH~2~O), 3.63--3.70 (m, 2H, CH~3~CH~2~O), 3.70--3.71 (m, H, CH), 3.74 (s, 3H, CH~3~O), 3.90--3.94 (m, 1H, CHN), 4.42--4.45 (m, 2H, CH~2~N), 6.91--6.94 (m, 2H, ArH), 7.19--7.21 (m, 2H, ArH), 8.06 (br, 1H, NH), 10.96 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.5, 15.5, 38.2, 41.5, 44.0, 46.3, 51.4, 55.6, 55.6, 56.5, 56.7, 96.2, 107.5, 114.5, 128.8, 153.6, 159.2, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~20~H~27~N~3~NaO~6~ \[M + Na\]^+^, 428.1792; found, 428.1796.

### (1*R*,5*R*)-9,9-Diethoxy-3-((4-fluorophenethyl)amino)-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3i**) {#sec4-2-9}

White solid; mp 181.3 °C; IR (KBr): 3421, 3188, 1719, 1619, 1511, 1382, 1079, 756 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.08--1.11 (m, 3H, CH~3~CH~2~O), 1.21--1.24 (m, 3H, CH~3~CH~2~O), 2.26--2.36 (m, 2H, COCH~2~, COCH~2~CHN), 2.67--2.71 (m, 1H, COCH~2~), 2.83--2.85 (m, 2H, CH~2~Ar), 2.87--2.88 (m, 1H, COCH~2~CHN), 3.43--3.50 (m, 4H, CH~2~N, CH~2~O), 3.61--3.65 (m, 4H, CH~2~O), 3.66--3.70 (m, 1H, CH), 3.92--3.96 (m, 1H, CHN), 7.12--7.15 (m, 2H, ArH), 7.28--7.31 (m, 2H, ArH), 8.05 (br, 1H, NH), 10.70 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.5, 15.6, 33.5, 38.1, 41.5, 42.6, 46.4, 51.4, 56.5, 56.7, 96.2, 107.4, 115.6 (d, *J* = 21.3 Hz), 131.1 (d, *J* = 7.5 Hz), 134.9 (d, *J* = 2.5 Hz), 153.5, 161.5 (d, *J* = 240.0 Hz), 208.4; ^13^F NMR (467 MHz, CDCl~3~): δ = −116.0; HRMS (EI^+^): *m*/*z* calcd for C~20~H~27~FN~3~O~5~ \[M + H\]^+^, 408.1929; found, 408.1934.

### (1*R*,5*R*)-3-((3-Chlorophenethyl)amino)-9,9-diethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3j**) {#sec4-2-10}

Yellow solid; mp 144.4 °C; IR (KBr): 3420, 3155, 1717, 1625, 1572, 1345, 1067, 756 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.07--1.10 (m, 3H, CH~3~CH~2~O), 1.19--1.22 (m, 3H, CH~3~CH~2~O), 2.35--2.38 (m, 1H, COCH~2~), 2.53--2.62 (m, 2H, COCH~2~, COCH~2~CHN), 2.75--2.83 (m, 3H, COCH~2~CHN, CH~2~Ar), 3.39--3.49 (m, 4H, CH~2~N, CH~2~O), 3.56--3.60 (m, 2H, CH~2~O), 3.79--3.83 (m, 1H, CH), 3.91--3.95 (m, 1H, CHN), 7.03--7.05 (m, 1H, ArH), 7.09--7.20 (m, 3H, ArH), 7.96 (br, 1H, NH), 10.89 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.2, 15.2, 34.3, 37.9, 41.1, 42.4, 46.0, 51.6, 56.5, 56.6, 96.0, 108.1, 127.0, 127.2, 128.7, 130.1, 134.2, 140.0, 153.6, 208.3; HRMS (EI^+^): *m*/*z* calcd for C~20~H~27~ClN~3~O~5~ \[M + H\]^+^, 424.1634; found, 424.1637.

### (1*R*,5*R*)-9,9-Diethoxy-4-nitro-3-(phenethylamino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3k**) {#sec4-2-11}

Yellow solid; mp 216.5--217.0 °C; IR (KBr): 3441, 3146, 1717, 1627, 1569, 1345, 1066, 755 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.09--1.12 (m, 3H, CH~3~CH~2~O), 1.21--1.24 (m, 3H, CH~3~CH~2~O), 2.27--2.37 (m, 2H, COCH~2~, COCH~2~ CHN), 2.68--2.71 (m, 1H, COCH~2~), 2.84--2.89 (m, 3H, COCH~2~CHN, CH~2~Ar), 3.45--3.51 (m, 4H, CH~2~O, CH~2~O), 3.61--3.65 (m, 2H, CH~2~N), 3.67--3.71 (m, 1H, CH), 3.93--3.97 (m, 1H, CHN), 7.22--7.33 (m, 5H, ArH), 8.07 (br, 1H, NH), 10.71 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.5, 15.6, 34.4, 38.1, 41.5, 42.6, 46.4, 51.4, 56.5, 56.7, 96.2, 107.4, 126.9, 128.9, 129.2, 138.8, 153.5, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~20~H~28~N~3~O~5~ \[M + H\]^+^, 390.2023; found, 390.2025.

### (1*R*,5*R*)-9,9-Diethoxy-4-nitro-3-((3-phenylpropyl)amino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3l**) {#sec4-2-12}

Yellow solid; mp 79.7 °C; IR (KBr): 3420, 1719, 1622, 1564, 1344, 1075, 753 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.07--1.09 (m, 3H, CH~3~CH~2~O), 1.19--1.24 (m, 3H, CH~3~CH~2~O), 1.82--1.87 (m, 2H, CH~2~CH~2~N), 2.25--2.28 (m, 1H, COCH~2~), 2.49--2.50 (m, 2H, CH~2~Ar), 2.59--2.62 (m, 1H, COCH~2~), 2.68--2.72 (m, 1H, COCH~2~), 2.85--2.89 (m, 1H, COCH~2~CHN), 3.20--3.23 (m, 2H, CH~2~N), 3.45--3.50 (m, 2H, CH~2~O), 3.51--3.70 (m, 2H, CH~2~O), 3.69--3.73 (m, 1H, CH), 3.92--3.96 (m, 1H, CHN), 7.17--7.21 (m, 3H, ArH), 7.26--7.31 (m, 3H, ArH), 8.00 (br, 1H, NH), 10.81 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.3, 15.5, 30.2, 32.5, 38.2, 41.5, 46.4, 51.4, 56.5, 56.7, 96.2, 107.5, 126.4, 128.7, 128.9, 128.9, 141.4, 153.7, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~21~H~30~N~3~O~5~ \[M + H\]^+^, 404.2180; found, 404.2185.

### (1*R*,5*R*)-3-((4-Fluorobenzyl)amino)-4-nitro-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**3m**) {#sec4-2-13}

White solid; mp 258.5--259.5 °C; IR (KBr): 3429, 1726, 1629, 1567, 1339, 1056, 755 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.24--2.27 (m, 1H, COCH~2~), 2.42--2.4 (m, 1H, COCH~2~CHN), 2.88--2.98 (m, 2H, COCH~2~, COCH~2~CHN), 3.45--3.49 (m, 1H, CH), 3.67--3.71 (m, 1H, CHN), 4.00--4.08 (m, 2H, CH~2~O), 4.15--7.4.17 (m, 2H, CH~2~O), 4.49--4.50 (m, 2H, CH~2~N), 7.21--7.24 (m, 2H, ArH), 7.32--7.35 (m, 2H, ArH), 8.19 (br, H, NH), 10.95 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 40.5, 42.6, 44.0, 47.3, 53.8, 65.4, 65.8, 103.6, 107.3, 115.9 (d, *J* = 21.3 Hz), 129.8 (d, *J* = 8.9 Hz), 133.3 (d, *J* = 2.5 Hz), 153.1, 162.0 (d, *J* = 242.5 Hz), 208.0; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −115.0; HRMS (EI^+^): *m*/*z* calcd for C~17~H~19~FN~3~O~5~ \[M + H\]^+^, 364.1303; found, 364.1305.

### (1*R*,5*R*)-3-(Benzylamino)-4-nitro-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**3n**) {#sec4-2-14}

Yellow solid; mp 237.3--237.8 °C; IR (KBr): 3419, 3250, 1720, 1619, 1558, 1381, 1254, 1053, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.17--2.21 (m, 1H, COCH~2~), 2.36--2.43 (m, 1H, COCH~2~CHN), 2.81--2.90 (m, 2H, COCH~2~, COCH~2~CHN), 3.39--3.43 (m, 1H, CH), 3.60--3.64 (m, 1H, CHN), 3.93--4.01 (m, 2H, CH~2~O), 4.07--4.09 (m, 2H, CH~2~O), 4.43--4.44 (m, 2H, CH~2~N), 7.20--7.33 (m, 5H, ArH), 8.12 (br, 1H, NH), 10.90 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 40.4, 42.7, 44.7, 47.3, 53.8, 65.4, 65.8, 103.7, 107.3, 127.6, 128.1, 129.2, 137.0, 153.3, 207.9; HRMS (EI^+^): *m*/*z* calcd for C~17~H~19~N~3~O~5~ \[M + H\]^+^, 346.1397; found, 346.1398.

### (1*R*,5*R*)-3-((3-Chlorophenethyl)amino)-4-nitro-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**3o**) {#sec4-2-15}

Yellow solid; mp 188.8 °C; IR (KBr): 3442, 3253, 1723, 1623, 1564, 1393, 1258, 1065, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 3.31--3.43 (m, 2H, COCH~2~, COCH~2~CHN), 2.83--2.91 (m, 3H, COCH~2~, CH~2~Ar), 2.91--2.98 (m, 1H, COCH~2~CHN), 3.41--3.50 (m, 3H, CH~2~N, CH~2~O), 3.68--3.72 (m, 1H, CH), 4.00--4.07 (m, 2H, CH~2~O), 4.12--4.19 (m, 2H, CH~2~O, CHN), 7.23--7.40 (m, 4H, ArH), 8.09--8.10 (m, 1H, NH), 10.67--10.70 (m, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 33.9, 40.2, 42.4, 42.7, 47.3, 53.7, 65.3, 65.8, 103.7, 107.1, 127.0, 128.1, 129.2, 130.7, 133.5, 141.3, 153.1, 208.0; HRMS (EI^+^): *m*/*z* calcd for C~18~H~21~ClN~3~O~5~ \[M + H\]^+^, 394.1164; found, 394.1164.

### (1*R*,5*R*)-4-Nitro-3-(phenethylamino)-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**3p**) {#sec4-2-16}

Yellow solid; mp 221.8--222.3 °C; IR (KBr): 3430, 3026, 1718, 1622, 1563, 1342, 1281, 1068, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.31--2.34 (m, 1H, COCH~2~), 2.40--2.43 (m, 1H, COCH~2~CHN), 2.85--2.91 (m, 3H, COCH~2~, CH~2~Ar), 2.94--2.98 (m, 1H, COCH~2~CHN), 3.40--4.49 (m, 3H, CH~2~N, CH), 3.67--3.71 (m, 1H, CHN), 4.00--4.07 (m, 2H, CH~2~O), 4.12--4.17 (m, 2H, CH~2~O), 7.23--7.34 (m, 5H, ArH), 8.09 (br, 1H, NH), 10.68 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 34.4, 42.7, 42.8, 47.3, 53.7, 65.3, 65.7, 103.7, 107.1, 127.0, 128.9, 129.3, 138.7, 153.1, 208.0; HRMS (EI^+^): *m*/*z* calcd for C~18~H~22~N~3~O~5~ \[M + H\]^+^, 360.1554; found, 360.1554.

### (1*R*,5*R*,9*R*)-3-((4-Fluorobenzyl)amino)-9-methoxy-9-methyl-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3q**) {#sec4-2-17}

Yellow solid; mp 137.1 °C; IR (KBr): 3444, 1717, 1620, 1570, 1512, 1383, 1225, 1061, 754 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.60 (s, 3H, CH~3~), 2.20--2.24 (m, 1H, COCH~2~), 2.36--2.40 (m, 1H, COCH~2~CHN), 2.75--2.80 (m, 1H, COCH~2~), 2.86--2.91 (m, 1H, COCH~2~CHN), 3.06--3.10 (m, 3H, OCH~3~), 3.49--3.53 (m, 1H, CH), 3.78--3.82 (m, 1H, CHN), 4.47--4.50 (m, 2H, CH~2~N), 7.19--7.23 (m, 2H, ArH), 7.29--7.32 (m, 2H, ArH), 7.98 (br, 1H, NH), 11.07 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 18.0, 40.2, 42.1, 43.6, 46.7, 49.3, 53.7, 71.5, 108.0, 115.8 (d, *J* = 21.4 Hz), 129.5 (d, *J* = 8.1 Hz), 133.5 (d, *J* = 2.8 Hz), 153.9, 161.9 (d, *J* = 241.8 Hz), 208.6; HRMS (EI^+^): *m*/*z* calcd for C~17~H~21~FN~3~O~4~ \[M + H\]^+^, 350.1511; found, 350.1513.

### (1*R*,5*R*,9*R*)-3-(Benzylamino)-9-methoxy-9-methyl-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3r**) {#sec4-2-18}

Yellow solid; mp 126.9 °C; IR (KBr): 3260, 1718, 1620, 1564, 1433, 1346, 1200, 1059, 741 cm^--1^; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ = 1.59--1.63 (s, 3H, CH~3~), 2.21--2.42 (m, 2H, COCH~2~, COCH~2~CHN), 2.80--2.91 (m, 2H, COCH~2~, COCH~2~CHN), 3.06--3.10 (m, 3H, OCH~3~), 3.51--3.53 (m, 1H, CH), 3.79--3.83 (m, 1H, CHN), 4.50--4.52 (m, 2H, CH~2~N), 7.25--7.40 (m, 5H, ArH), 8.01 (br, 1H, NH), 11.11 (br, 1H, NH); ^13^C NMR (100 MHz, DMSO-*d*~6~): δ = 19.0, 40.2, 42.2, 44.4, 46.7, 49.3, 53.7, 71.5, 108.0, 127.8 (d, *J* = 10.2 Hz), 129.1, 137.2, 154.0, 208.6; HRMS (EI^+^): *m*/*z* calcd for C~17~H~22~N~3~O~4~ \[M + H\]^+^, 332.1605; found, 332.1606.

### (1*R*,5*R*,8*S*)-9,9-Dimethoxy-3-((4-methoxybenzyl)amino)-8-methyl-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3s**) {#sec4-2-19}

White solid; mp 254.8--255.8 °C; IR (KBr): 3421, 3243, 1720, 1614, 1554, 1398, 1275, 1036, 756 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 0.74--0.76 (m, 3H, CH~3~), 2.35--2.38 (m, 1H, COCH~2~), 2.68--2.71 (m, 1H, COCH~2~), 2.83--2.85 (m, 1H, COCH), 3.17 (s, 3H, OCH~3~), 3.36 (m, 3H, OCH~3~), 3.73--3.74 (m, 1H, CH), 3.75--3.79 (m, 1H, CHN), 4.54--4.55 (m, 2H, CH~2~N), 7.21--7.23 (m, 2H, ArH), 7.29--7.32 (m, 1H, ArH), 7.36--7.39 (m, 1H, ArH), 7.92 (br, 1H, NH), 11.05 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 10.9, 38.4, 41.2, 44.4, 46.1, 48.7, 49.0, 55.4, 56.2, 96.9, 107.3, 127.3 (d, *J* = 16.3 Hz), 127.9, 129.1, 137.1, 153.9, 209.6; HRMS (EI^+^): *m*/*z* calcd for C~19~H~26~N~3~O~6~ \[M + H\]^+^, 392.1816; found, 392.1817.

### (1*R*,5*R*,8*S*)-9,9-Dimethoxy-3-((4-methoxyphenethyl)amino)-8-methyl-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3t**) {#sec4-2-20}

Yellow solid; mp 171.3 °C; IR (KBr): 3445, 1717, 1623, 1563, 1514, 1349, 1247, 1081, 758 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 0.96--0.97 (s, 3H, CH~3~), 2.33--2.37 (m, 1H, COCH~2~), 2.69--2.70 (m, 2H, COCH~2~), 2.78--2.81 (m, 2H, CH~2~Ar), 2.85--2.88 (m, 1H, COCH), 3.17 (s, 3H, CH~3~O), 3.36 (s, 3H, CH~3~O), 3.71--3.74 (m, 2H, CH), 3.80--3.84 (m, 2H, CHN), 6.87--6.89 (m, 2H, ArH), 7.17--7.18 (m, 2H, ArH), 7.93 (br, 1H, NH), 10.70 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 11.2, 33.5, 38.3, 41.2, 43.0, 46.1, 48.7, 49.0, 55.5, 56.3, 96.8, 107.2, 114.3, 130.2, 130.6, 153.7, 158.5, 209.8; HRMS (EI^+^): *m*/*z* calcd for C~20~H~28~N~3~O~6~ \[M + H\]^+^, 406.1973; found, 406.1969.

### (1*R*,5*R*,8*S*)-9,9-Dimethoxy-8-methyl-4-nitro-3-(phenethylamino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3u**) {#sec4-2-21}

White solid; mp 241.5--242.0 °C; IR (KBr): 3425, 3260, 1718, 1623, 1563, 1348, 1274, 1079, 756 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 0.96--0.97 (s, 3H, CH~3~), 2.32--2.33 (m, 1H, COCH~2~), 2.68--2.72 (m, 1H, COCH~2~), 2.84--2.86 (m, 2H, ArCH~2~), 2.89--2.91 (m, 1H, COCH), 3.17 (s, 3H, OCH~3~), 3.35 (s, 3H, OCH~3~), 3.45--3.48 (m, 2H, CH~2~N), 3.71 (s, 1H, CH), 3.80 (s, 1H, CHN), 7.22--7.33 (m, 5H, ArH), 7.93 (br, 1H, NH), 10.71 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 11.2, 34.4, 38.2, 41.2, 42.8, 46.1, 48.7, 49.0, 56.3, 96.8, 107.2, 127.0, 128.9, 129.2, 138.8, 153.7, 209.8; HRMS (EI^+^): *m*/*z* calcd for C~19~H~26~N~3~O~5~ \[M + H\]^+^, 376.1867; found, 376.1869.

### (1*R*,5*R*)-3-((4-Fluorophenethyl)amino)-9,9-dimethoxy-1-methyl-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3v**) {#sec4-2-22}

Yellow solid; mp 241.5--242.0 °C; IR (KBr): 3424, 3267, 1721, 1623, 1552, 1509, 1395, 1270, 1067, 756 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.35--1.39 (m, 3H, CH~3~), 2.21--2.28 (m, 2H, COCH~2~), 2.72--2.76 (m, 1H, COCH~2~CHN), 2.85--2.88 (m, 3H, COCH~2~CHN, CH~2~Ar), 3.27 (s, 3H, OCH~3~), 3.45 (s, 3H, OCH~3~), 3.45--3.51 (m, 2H, CH~2~N), 3.84--3.88 (m, 1H, CH), 3.89--3.90 (m, 1H, CHN), 7.11--7.15 (m, 2H, ArH), 7.30 (br, 2H, ArH), 7.57 (br, 1H, NH), 10.71 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 21.6, 33.5, 37.3, 42.0, 42.8, 50.9, 51.2, 53.5, 61.8, 97.0, 107.0, 115.6 (d, *J* = 20.0 Hz), 131.1 (d, *J* = 8.8 Hz), 134.9 (d, *J* = 2.5 Hz), 153.0, 161.5 (d, *J* = 240.0 Hz), 208.0; HRMS (EI^+^): *m*/*z* calcd for C~19~H~25~FN~3~O~5~ \[M + H\]^+^, 394.1773; found, 394.1772.

### (1*R*,5*R*)-9,9-Dimethoxy-1-methyl-3-((4-methylphenethyl)amino)-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3w**) {#sec4-2-23}

Yellow solid; mp 233.5--234.0 °C; IR (KBr): 3440, 3276, 1718, 1625, 1560, 1513, 1359, 1060, 756 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.24--1.28 (m, 3H, CH~3~), 2.21--2.24 (m, 4H, CH~3~, COCH~2~), 2.50--2.53 (m, 1H, COCH~2~CHN), 2.63--2.67 (m, 2H, COCH~2~, COCH~2~CHN), 2.74--2.77 (m, 2H, CH~2~Ar), 3.24 (s, 3H, OCH~3~), 3.38--3.42 (m, 2H, CH~2~N), 3.39--3.43 (m, 1H, CH), 3.40 (s, 3H, OCH~3~), 3.98--3.99 (m, 1H, CHN), 5.99 (br, 1H, NH), 6.98--7.03 (m, 4H, ArH), 10.83 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 21.1, 21.8, 34.5, 37.1, 41.7, 43.1, 50.8, 51.2, 53.1, 61.6, 96.9, 107.6, 128.6, 129.7, 134.9, 136.4, 153.1, 207.9; HRMS (EI^+^): *m*/*z* calcd for C~20~H~28~N~3~O~5~ \[M + H\]^+^, 390.2023; found, 390.2024.

### (1*R*,5*R*)-9,9-Dimethoxy-3-((4-methoxyphenethyl)amino)-1-methyl-4-nitro-2-azabicyclo-\[3.3.1\]non-3-en-7-one (**3x**) {#sec4-2-24}

Yellow solid; mp 216.2--216.7 °C; IR (KBr): 3424, 3278, 1718, 1625, 1556, 1514, 1360, 1245, 1074, 757 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.36--1.40 (m, 3H, CH~3~), 2.21--2.28 (m, 2H, COCH~2~), 2.72--2.73 (m, 1H, COCH~2~CHN), 2.76--2.81 (m, 2H, CH~2~Ar), 2.85--2.88 (m, 1H, COCH~2~CHN), 3.25--3.29 (m, 3H, CH~3~O), 3.45--3.46 (m, 3H, CH~3~O), 3.41--3.45 (m, 1H, CH), 3.71--3.75 (m, 3H, CH~3~O), 3.88--3.90 (m, 1H, CHN), 6.86--6.88 (m, 2H, ArH), 7.04 (br, 1H, NH), 7.17--7.19 (m, 2H, ArH), 10.70 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 21.6, 33.5, 37.3, 42.0, 43.1, 50.9, 51.2, 53.5, 55.5, 61.8, 97.0, 107.0, 114.3, 130.3, 130.6, 153.0, 158.5, 208.1; HRMS (EI^+^): *m*/*z* calcd for C~20~H~28~N~3~O~6~ \[M + H\]^+^, 406.1973; found, 406.1978.

### (1*R*,5*R*)-3-((4-Chlorophenyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**3y**) {#sec4-2-25}

Yellow solid; mp \> 300 °C; IR (KBr): 3415, 1706, 1618, 1561, 1372, 1296, 1079, 760 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.22--2.25 (m, 1H, COCH~2~), 2.32--2.35 (m, 1H, COCH~2~), 2.65--2.68 (m, 1H, COCH~2~CH), 2.74--2.77 (m, 1H, COCH~2~CH), 3.12 (s, 3H, OCH~3~), 3.28 (s, 3H, OCH~3~), 3.70--43.71 (m, 1H, CH), 3.81--3.85 (m, 1H, CHN), 7.22--7.24 (m, 2H, ArH), 7.46--7.48 (m, 2H, ArH), 7.89 (br, 1H, NH), 12.02 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.4, 41.5, 45.9, 48.8, 49.0, 50.9, 96.4, 108.0, 127.8, 130.3, 131.8, 134.4, 152.6, 208.3; HRMS (EI^+^): *m*/*z* calcd for C~16~H~18~ClN~3~NaO~5~ \[M + Na\]^+^, 390.0827; found, 390.0833.

### (1*R*,5*R*)-Ethyl 9,9-Dimethoxy-3-(methylamino)-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**3z**) {#sec4-2-26}

White solid; mp 184.2 °C; IR (KBr): 3432, 2977, 1638, 1542, 1450, 1320, 1158, 1065, 779 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.10--1.13 (m, 3H, CH~3~CH~2~O), 2.17--2.20 (m, 1H, COCH~2~), 2.34--2.37 (m, 1H, COCH~2~), 2.58--2.61 (m, 1H, COCH~2~CHN), 2.63--2.66 (m, 1H, COCH~2~CHN), 2.87 (s, 3H, OCH~3~), 3.14 (s, 3H, CH~3~NH), 3.17--3.21 (m, 1H, CH), 3.32 (s, 3H, OCH~3~), 3.73--3.77 (m, 1H, CHN), 3.89--3.98 (m, 2H, CH~2~O), 7.33 (br, 2H, NH, NHCH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.4, 34.7, 35.9, 43.0, 45.7, 48.5, 48.6, 57.6, 59.4, 72.5, 97.1, 157.9, 168.3, 210.0; HRMS (EI^+^): *m*/*z* calcd for C~14~H~22~NaN~2~O~4~ \[M + Na\]^+^, 321.1421; found, 321.1422.

### (1*R*,5*R*)-Ethyl 9,9-Diethoxy-3-(methylamino)-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**3a′**) {#sec4-2-27}

White solid; mp 156.6 °C; IR (KBr): 3472, 2974, 1640, 1537, 1441, 1320, 1164, 1069, 776 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.08--1.14 (m, 6H, CH~3~CH~2~O, CH~3~CH~2~O), 1.18--1.21 (m, 3H, CH~3~CH~2~O), 2.18--2.21 (m, 1H, COCH~2~), 2.32--2.35 (m, 1H, COCH~2~), 2.58--2.65 (m, 1H, COCH~2~CHN), 2.67--2.68 (m, 1H, COCH~2~CH), 2.87 (s, 3H, CH~3~NH), 3.29--3.33 (m, 1H, CH), 3.45--3.48 (m, 2H, CH~3~CH~2~O), 3.55--3.59 (m, 2H, CH~3~CH~2~O), 3.73 (m, 1H, CHN), 3.89--3.99 (m, 2H, CH~3~CH~2~O), 7.35 (br, 2H, NH, NHCH~3~); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.4, 15.6, 15.7, 35.6, 36.0, 43.2, 45.8, 56.2, 56.3, 57.6, 60.2, 72.8, 96.9, 158.0, 168.3, 210.0; HRMS (EI^+^): *m*/*z* calcd for C~16~H~27~N~2~O~5~ \[M + H\]^+^, 327.1914; found, 327.1918.

### (1*R*,5*R*)-Ethyl 3-Amino-9,9-dimethoxy-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**3b′**) {#sec4-2-28}

Yellow solid; mp 170.5 °C; IR (KBr): 3414, 2959, 1638, 1537, 1372, 1086, 755 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.21--1.24 (m, 3H, CH~3~CH~2~O), 2.31--2.35 (m, 1H, COCH~2~), 2.42--2.45 (m, 1H, COCH~2~), 2.70--2.77 (m, 2H, COCH~2~CHN), 3.28 (s, 3H, OCH~3~), 3.34--3.38 (m, 1H, CH), 3.38 (s, 3H, OCH~3~), 3.77--3.81 (m, 1H, CHN), 4.00--4.10 (m, 2H, CH~2~O), 5.57--5.58 (m, 1H, NH), 6.36 (br, 2H, NH~2~); ^13^C NMR (125 MHz, CDCl~3~): δ = 14.7, 34.4, 44.9, 46.7, 48.5, 48.6, 50.8, 58.4, 73.6, 97.3, 156.5, 169.1, 211.7; HRMS (EI^+^): *m*/*z* calcd for C~13~H~19~N~2~O~5~ \[M -- H\]^−^, 283.1299; found, 283.1303.

### (1*R*,5*R*)-Ethyl 3-Amino-9,9-diethoxy-7-oxo-2-azabicyclo\[3.3.1\]non-3-ene-4-carboxylate (**3c′**) {#sec4-2-29}

Yellow liquid; IR (KBr): 3413, 2976, 1639, 1538, 1372, 1083, 780 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.18--1.28 (m, 12H, CH~3~CH~2~O, CH~3~CH~2~O, CH~3~), 2.33--2.36 (m, 1H, COCH~2~), 2.45--2.48 (m, 1H, COCH~2~), 2.73--2.80 (m, 2H, COCH~2~CHN), 3.34--3.38 (m, 1H, CH), 3.53--3.62 (m, 4H, CH~2~O, CH~3~CH~2~O), 3.75--3.79 (m, 1H, CHN), 4.01--4.12 (m, 2H, CH~3~CH~2~O), 4.93 (br, 1H, NH), 6.15 (br, 2H, NH~2~); ^13^C NMR (125 MHz, CDCl~3~): δ = 14.8, 15.3, 15.3, 29.7, 35.0, 45.0, 46.9, 52.0, 56.4, 56.4, 58.5, 97.1, 156.0, 169.4, 211.8; HRMS (EI^+^): *m*/*z* calcd for C~15~H~24~N~2~NaO~5~ \[M + Na\]^+^, 335.1577; found, 335.1578.

General Procedure for the Synthesis of Compounds **4** {#sec4-3}
------------------------------------------------------

Quinone monoketals **1** (1.1 mmol), EDAMs **2** (1.0 mmol), Cs~2~CO~3~ (2.0 mmol), and 1,4-dioxane (15 mL) were charged into a 25 mL round-bottom flask. The mixture was kept at reflux for about 6 h and monitored by TLC until the quinone monoketal **1** substrate was completely consumed. After the reaction was completed, the reaction system was cooled to room temperature. The reaction mixture was poured into 25 mL of water and 50 mL of ethyl acetate for extraction and separation. Then, the crude product was concentrated by distillation under reduced pressure, purified by column chromatography (petroleum ether/ethyl acetate = 2:1), and produced a series of compounds **4** in a 65--89% yield.

### (1*R*,5*R*)-2-(4-Fluorobenzyl)-3-((4-fluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4a**) {#sec4-3-1}

Yellow solid; mp 158.6 °C; IR (KBr): 3409, 1714, 1585, 1511, 1474, 1358, 1223, 1087, 716 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.48--2.51 (m, 2H, COCH~2~), 2.75--2.78 (m, 2H, COCH~2~CHN), 3.12 (s, 3H, OCH~3~), 3.28 (s, 3H, OCH~3~), 3.79--3.80 (m, 1H, CH), 3.32--3.36 (m, 1H, CHN), 4.43--4.44 (m, 2H, CH~2~N), 4.76--4.78 (m, 2H, CH~2~N), 6.93--7.08 (m, 6H, ArH), 7.17--7.20 (m, 4H, ArH), 7.24--7.28 (m, 2H, ArH), 7.40--7.43 (m, 2H, ArH), 11.54 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.2, 41.2, 44.0, 48.8, 49.0, 49.1, 56.0, 59.4, 96.2, 111.2, 116.0, 116.1, 129.2 (d, *J* = 7.5 Hz), 129.7 (d, *J* = 7.5 Hz), 133.3 (d, *J* = 202.5 Hz), 133.3 (d, *J* = 202.5 Hz), 158.7, 162.1 (d, *J* = 242.5 Hz), 162.5 (d, *J* = 242.5 Hz), 207.4; ^19^F NMR (467 MHz, CDCl~3~): δ = −114.9, −114.5; HRMS (EI^+^): *m*/*z* calcd for C~24~H~26~FN~3~O~5~ \[M + H\]^+^, 474.1835; found, 474.1836.

### (1*R*,5*R*)-9,9-Dimethoxy-2-(4-methoxybenzyl)-3-((4-methoxybenzyl)amino)-4-nitro-2-aza-bicyclo\[3.3.1\]non-3-en-7-one (**4b**) {#sec4-3-2}

Yellow solid; mp 74.8 °C; IR (KBr): 3421, 1717, 1613, 1513, 1461, 1351, 1250, 1094, 820 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.42--2.46 (m, 1H, COCH~2~), 2.54--2.56 (m, 1H, COCH~2~), 2.75--2.78 (m, 2H, COCH~2~CHN), 3.18 (s, 3H, OCH~3~), 3.22 (s, 3H, OCH~3~), 3.52--3.53 (m, 1H, CH), 3.71 (s, 3H, CH~3~OAr), 3.75 (s, 3H, CH~3~OAr), 3.95--3.96 (m, 1H, CHN), 4.28--4.29 (m, 1H, CH~2~N), 4.34--4.36 (m, 1H, CH~2~N), 4.47--4.49 (m, 2H, CH~2~N), 6.76--6.78 (m, 2H, ArH), 6.85--6.87 (m, 2H, ArH), 6.96--6.97 (m, 2H, ArH), 7.13--7.20 (m, 2H, ArH), 11.62 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 36.8, 41.0, 44.0, 48.7, 49.1, 49.3, 55.3, 55.4, 57.2, 58.2, 96.4, 111.3, 111.4, 114.6, 126.7, 127.9, 128.0, 128.8, 159.4, 159.5, 159.7, 207.1; HRMS (EI^+^): *m*/*z* calcd for C~26~H~32~N~3~O~7~ \[M + H\]^+^, 498.2235; found, 498.2239.

### (1*R*,5*R*)-2-(2,4-Difluorobenzyl)-3-((2,4-difluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4c**) {#sec4-3-3}

Yellow solid; mp 197.1 °C; IR (KBr): 3420, 1716, 1620, 1505, 1431, 1365, 1280, 1032, 773 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.46--2.49 (m, 1H, COCH~2~), 2.60--2.65 (m, 1H, COCH~2~CH), 2.73--2.77 (m, 2H, COCH~2~, COCH~2~CH), 3.15 (s, 3H, OCH~3~), 3.21 (s, 3H, OCH~3~), 3.51--3.55 (m, 1H, CH), 3.86--3.90 (m, 1H, CHN), 4.29--4.35 (m, 2H, CH~2~N), 4.42--4.46 (m, 1H, CH~2~N), 4.67--4.71 (m, 1H, CH~2~N), 6.67--6.71 (m, 1H, ArH), 6.77--6.82 (m, 2H, ArH), 6.86--6.89 (m, 1H, ArH), 7.11--7.16 (m, 1H, ArH), 7.32--7.36 (m, 1H, ArH), 11.19 (m, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 36.6, 40.9, 43.7, 43.9, 48.7, 48.9, 51.8, 58.2, 96.1, 104.1--104.2 (m), 104.3--104.4 (m), 104.5--104.7 (m), 111.7--111.8 (m), 111.8, 111.8--112.0 (m), 118.4 (d, *J* = 17.5 Hz), 119.9 (d, *J* = 17.5 Hz), 129.1 (d, *J* = 13.8 Hz), 129.9 (d, *J* = 15.0 Hz), 159.4--159.8 (m), 160.1, 161.4--161.9 (m), 163.8--163.9 (m), 206.6; ^19^F NMR (467 MHz, CDCl~3~): δ = −113.9 (d, *J* = 4.7 Hz), −112.4 (d, *J* = 4.7 Hz), −109.3 (d, *J* = 4.7 Hz), −109.2 (d, *J* = 4.7 Hz); HRMS (EI^+^): *m*/*z* calcd for C~24~H~24~F~4~N~3~O~5~ \[M + H\]^+^, 510.1647; found, 510.1647.

### (1*R*,5*R*)-2-(3,4-Difluorobenzyl)-3-((3,4-difluorobenzyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4d**) {#sec4-3-4}

Yellow solid; mp 178.2 °C; IR (KBr): 3420, 1720, 1581, 1519, 1434, 1347, 1298, 1039, 780 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.45--2.51 (m, 1H, COCH~2~), 2.75--2.80 (m, 2H, COCH~2~CH), 3.13 (s, 3H, OCH~3~), 3.28 (s, 3H, OCH~3~), 3.77--3.81 (m, 1H, CH), 3.87--3.91 (m, 2H, CHN), 4.41--4.42 (m, 2H, CH~2~N), 4.69--4.80 (m, 2H, CH~2~N), 6.97--7.01 (m, 1H, ArH), 7.17--7.20 (m, 2H, ArH), 7.38--7.49 (m, 3H, ArH), 11.34 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 37.1, 41.2, 44.0, 48.4, 49.0, 49.1, 55.7, 59.6, 96.1, 111.4, 116.4--116.5 (m), 116.6--116.7 (m), 118.2, 118.3, 123.9, 124.3--124.4 (m), 134.1, 135.8, 148.2--148.4, 148.8--149.0, 150.2--150.4, 150.8--151.0, 158.8, 207.3; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −140.3 (d, *J* = 23.4 Hz), −140.3 (d, *J* = 23.4 Hz), −138.0 (d, *J* = 18.7 Hz), −138.0 (d, *J* = 23.4 Hz); HRMS (EI^+^): *m*/*z* calcd for C~24~H~24~F~4~N~3~O~5~ \[M + H\]^+^, 510.1647; found, 510.1648.

### (1*R*,5*R*)-2-(4-Fluorophenethyl)-3-((4-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4e**) {#sec4-3-5}

Yellow solid; mp 140.8 °C; IR (KBr): 3419, 1713, 1618, 1579, 1468, 1351, 1229, 1066, 760 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 2.44--2.51 (m, 2H, COCH~2~), 2.71--2.75 (m, 1H, COCH~2~CH), 2.84--2.89 (m, 1H, COCH~2~CH), 2.91--2.96 (m, 2H, CH~2~Ar), 3.01--3.04 (m, 2H, CH~2~Ar), 3.18 (s, 3H, OCH~3~), 3.36 (s, 3H, OCH~3~), 3.46--3.50 (m, 1H, CH), 3.58--3.68 (m, 2H, CH~2~N), 3.69--4.13 (m, 2H, CH~2~N), 4.11--4.15 (m, 2H, CHN), 7.12--7.19 (m, 4H, ArH), 7.28--7.40 (m, 3H, ArH), 7.42--7.43 (m, 1H, ArH), 11.08 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 27.3, 29.5, 37.2, 41.0, 44.8, 46.5, 49.1, 54.0, 58.7, 96.1, 110.8, 115.6--115.8 (m), 124.7--124.8 (m), 125.0--125.1 (m), 129.3--129.4 (m), 131.4--131.8 (m), 159.0, 161.1 (d, *J* = 241.3 Hz), 161.2 (d, *J* = 242.5 Hz), 207.5; ^19^F NMR (467 MHz, DMSO-*d*~6~): δ = −118.4, −118.3; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~F~2~N~3~O~5~ \[M + H\]^+^, 502.2148; found, 502.2149.

### (1*R*,5*R*)-2-(3-Fluorophenethyl)-3-((3-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4f**) {#sec4-3-6}

Yellow solid; mp 65.2 °C; IR (KBr): 3420, 2924, 1716, 1590, 1452, 1352, 1091, 782 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.33--2.36 (m, 1H, COCH~2~), 2.64--2.70 (m, 3H, COCH~2~, COCH~2~CH), 2.82--2.90 (m, 4H, CH~2~Ar), 3.14 (s, 3H, OCH~3~), 3.27 (s, 3H, OCH~3~), 3.36--3.39 (m, 1H, CH~2~N), 3.45--3.48 (m, 3H, CH~2~N, CH~2~N), 3.59--3.63 (m, 1H, CH), 3.79--3.83 (m, 1H, CHN), 6.76--6.93 (m, 6H, ArH), 7.19--7.23 (m, 2H, ArH), 11.07 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 34.2, 36.2, 36.6, 40.8, 44.7, 48.7, 48.8, 49.0, 55.9, 59.1, 95.9, 111.2, 114.0--114.1 (m), 114.1--114.2 (m), 115.4, 115.5, 124.1--124.2 (m), 124.4, 130.4--130.5, 130.5--130.6, 139.5--139.6, 139.8--139.9, 159.6, 162.0, 164.0, 206.9; ^19^F NMR (467 MHz, CDCl~3~): δ = −112.6, −112.2; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~F~2~N~3~O~5~ \[M + H\]^+^, 502.2148; found, 502.2149.

### (1*R*,5*R*)-2-(2-Fluorophenethyl)-3-((2-fluorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4g**) {#sec4-3-7}

Yellow solid; mp 61.0 °C; IR (KBr): 3424, 1714, 1580, 1493, 1458, 1351, 1229, 1068, 759 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.38--2.41 (m, 1H, COCH~2~), 2.73--2.76 (m, 3H, COCH~2~, COCH~2~CHN), 2.94--2.98 (m, 4H, CH~2~Ar, CH~2~Ar), 3.17 (s, 3H, OCH~3~), 3.33 (m, 3H, OCH~3~), 3.46--3.52 (m, 3H, CH~2~N, CH~2~N), 3.63--3.66 (m, 1H, CH~2~N), 3.70--3.74 (m, 1H, CH), 3.82--3.86 (m, 1H, CHN), 6.98--7.07 (m, 4H, ArH), 7.12--7.23 (m, 4H, ArH), 11.16 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 28.2, 30.5, 36.6, 40.7, 44.7, 47.1, 48.7, 48.9, 54.9, 58.8, 95.9, 111.1, 115.5, 115.7, 123.8, 124.0, 124.5, 124.6, 129.0, 129.2, 131.3, 131.3, 159.6, 161.1 (d, *J* = 243.8 Hz), 161.1 (d, *J* = 243.8 Hz), 206.9; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~F~2~N~3~O~5~ \[M + H\]^+^, 502.2148; found, 502.2149.

### (1*R*,5*R*)-2-(4-Chlorophenethyl)-3-((4-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4h**) {#sec4-3-8}

Yellow solid; mp 168.5 °C; IR (KBr): 3414, 1717, 1589, 1494, 1355, 1039, 775 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.33--2.36 (m, 1H, COCH~2~), 2.64--2.65 (m, 1H, COCH~2~CH), 2.69--2.71 (m, 2H, COCH~2~, COCH~2~CH), 2.81--2.88 (m, 4H, CH~2~Ar), 3.13 (s, 3H, OCH~3~), 3.28 (s, 3H, OCH~3~), 3.33--3.37 (m, 1H, CH~2~N), 3.41--3.47 (m, 1H, CH~2~N), 3.56--3.60 (m, 1H, CH), 3.79--3.83 (m, 1H, CHN), 6.98--6.99 (m, 2H, ArH), 7.06--7.08 (m, 2H, ArH), 7.20--7.22 (m, 4H, ArH), 11.05 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 33.9, 35.8, 36.6, 40.8, 44.8, 48.7, 49.0, 49.0, 56.0, 59.2, 95.9, 111.1, 129.0, 129.1, 129.8, 130.0, 133.2, 133.1, 135.5, 135.9, 159.6, 206.8; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~Cl~2~N~3~O~5~ \[M + H\]^+^, 534.1557; found, 534.1561.

### (1*R*,5*R*)-2-(3-Chlorophenethyl)-3-((3-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4i**) {#sec4-3-9}

Yellow solid; mp 74.5 °C; IR (KBr):3422, 1716, 1599, 1465, 1351, 1075, 782 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.38--2.42 (m, 1H, COCH~2~), 2.71--2.77 (m, 3H, COCH~2~, COCH~2~CHN), 2.87--2.95 (m, 4H, CH~2~Ar, CH~2~Ar), 3.20 (s, 3H, OCH~3~), 3.34 (s, 3H, OCH~3~), 3.41--3.44 (m, 1H, CH~2~N), 3.51--3.55 (m, 2H, CH~2~N), 3.67--3.71 (m, 1H, CH~2~N), 3.67--3.71 (m, 1H, CH), 3.86--3.87 (m, 1H, CHN), 7.00--7.24 (m, 8H, ArH), 11.13 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 34.1, 36.1, 36.6, 40.8, 44.7, 48.7, 48.8, 49.0, 55.8, 59.1, 95.9, 111.2, 126.7, 127.0, 127.3, 127.4, 128.6, 128.6, 130.2, 130.3, 134.5, 134.7, 139.1, 139.5, 159.6, 206.9; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~Cl~2~N~3~O~5~ \[M + H\]^+^, 534.1557; found, 534.1559.

### (1*R*,5*R*)-2-(2-Chlorophenethyl)-3-((2-chlorophenethyl)amino)-9,9-dimethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4j**) {#sec4-3-10}

Yellow solid; mp 124.1 °C; IR (KBr): 3422, 1715, 1575, 1465, 1349, 1094, 759 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.44--2.51 (m, 2H, COCH~2~), 2.72--2.76 (m, 1H, COCH~2~CHN), 2.87--2.91 (m, 1H, COCH~2~CHN), 3.00--3.03 (m, 2H, CH~2~Ar), 3.09--3.12 (m, 2H, CH~2~Ar), 3.19 (s, 3H, OCH~3~), 3.37 (s, 3H, OCH~3~), 3.43--3.47 (m, 1H, CH~2~N), 3.54--3.61 (m, 2H, CH~2~N), 3.68--3.69 (m, 1H, CH), 3.72--3.75 (m, 1H, CH~2~N), 4.11--4.15 (m, 1H, CHN), 7.25--7.32 (m, 4H, ArH), 7.35--7.36 (m, 1H, ArH), 7.39--7.41 (m, 1H, ArH), 7.44--7.48 (m, 1H, ArH), 11.06 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 31.4, 34.1, 37.2, 41.0, 44.9, 46.5, 49.1, 49.2, 54.1, 58.4, 96.1, 110.9, 127.8, 128.0, 129.2, 129.2, 129.9, 131.4, 131.8, 133.5, 133.6, 135.6, 135.7, 137.4, 159.2, 207.3; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~Cl~2~N~3~O~5~ \[M + H\]^+^, 534.1557; found, 534.1557.

### (1*R*,5*R*)-9,9-Dimethoxy-4-nitro-2-phenethyl-3-(phenethylamino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4k**) {#sec4-3-11}

Yellow liquid; IR (KBr): 3421, 1716, 1587, 1455, 1352, 1262, 1069, 700 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.29--2.32 (m, 1H, COCH~2~), 2.59--2.67 (m, 3H, COCH~2~, COCH~2~CH), 2.79--2.85 (m, 4H, CH~2~Ar, CH~2~Ar), 3.09 (s, 3H, OCH~3~), 3.22 (s, 3H, OCH~3~), 3.36--3.50 (m, 4H, CH~2~N), 3.59--3.63 (m, 1H, CH), 3.76--3.80 (m, 1H, CHN), 7.02--7.04 (m, 2H, ArH), 7.10--7.20 (m, 8H, ArH), 11.15 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 34.6, 36.5, 36.7, 40.8, 44.7, 48.7, 48.9, 49.1, 56.2, 59.0, 95.9, 111.0, 127.0, 127.2, 128.5, 128.7, 128.8, 129.0, 137.1, 137.5, 159.6, 207.1; HRMS (EI^+^): *m*/*z* calcd for C~26~H~32~N~3~O~5~ \[M + H\]^+^, 466.2336; found, 466.2339.

### (1*R*,5*R*)-9,9-Dimethoxy-2-(4-methylphenethyl)-3-((4-methylphenethyl)amino)-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4l**) {#sec4-3-12}

Yellow liquid; IR (KBr): 3472, 1717, 1591, 1461, 1350, 1261, 1092, 716 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.24 (s, 6H, CH~3~Ar), 2.29--2.32 (m, 1H, COCH~2~), 2.59--2.61 (m, 1H, COCH~2~), 2.68--2.71 (m, 1H, COCH~2~CH), 2.80--2.86 (m, 4H, CH~2~Ar, CH~2~Ar), 3.12 (s, 3H, OCH~3~), 3.25 (s, 3H, OCH~3~), 3.38--3.54 (m, 4H, CH~2~N, CH~2~N), 3.54--3.55 (m, 1H, CH), 3.80--3.81 (m, 1H, CHN), 6.93--7.05 (m, 8H, ArH), 11.15 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 21.1, 21.1, 34.2, 36.1, 36.6, 40.8, 44.7, 48.7, 49.0, 49.3, 56.5, 58.9, 96.1, 111.0, 128.4, 128.6, 129.5, 129.5, 129.6, 129.6, 133.9, 134.4, 136.7, 136.9, 159.6, 207.0; HRMS (EI^+^): *m*/*z* calcd for C~28~H~36~N~3~O~5~ \[M + H\]^+^, 494.2649; found, 494.2651.

### (1*R*,5*R*)-9,9-Dimethoxy-4-nitro-2-(3-phenylpropyl)-3-((3-phenylpropyl)amino)-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4m**) {#sec4-3-13}

Yellow solid; mp 163.8 °C; IR (KBr): 3417, 1716, 1603, 1561, 1453, 1350, 1201, 1054, 752 cm^--1^; ^1^H NMR (500 MHz, DMSO): δ = 1.68--1.74 (m, 3H, CH~2~CH~2~N, COCH~2~), 1.93--1.97 (m, 1H, COCH~2~), 2.34--2.37 (m, 1H, COCH~2~CH), 2.47--2.58 (m, 6H, CH~2~Ar, CH~2~Ar, CH~2~CH~2~N), 2.71--2.75 (m, 2H, CH~2~N), 2.83--2.87 (m, 2H, CH~2~N), 2.93--2.97 (m, 1H, COCH~2~CH), 2.85--2.89 (m, 1H, CH~2~Ar), 3.16 (s, 3H, OCH~3~), 3.31 (s, 3H, OCH~3~), 3.68--3.72 (m, 1H, CH), 3.98--4.02 (m, 1H, CHN), 7.12--7.30 (m, 10H, ArH), 11.19 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 29.6, 31.7, 32.1, 32.3, 37.4, 41.0, 44.9, 45.7, 49.1, 53.2, 58.7, 96.1, 110.4, 126.5, 128.8, 128.8, 128.8, 128.9, 128.9, 128.9, 128.9, 141.1 (d, *J* = 20.0 Hz), 158.8, 207.6; HRMS (EI^+^): *m*/*z* calcd for C~28~H~36~N~3~O~5~ \[M + H\]^+^, 494.2649; found, 494.2652.

### (1*R*,5*R*)-2-Benzyl-3-(benzylamino)-9,9-diethoxy-4-nitro-2-azabicyclo\[3.3.1\]non-3-en-7-one (**4n**) {#sec4-3-14}

Yellow liquid; IR (KBr): 3423, 1716, 1592, 1453, 1351, 1075, 733 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 1.11--1.14 (m, 6H, CH~3~CH~2~O, CH~3~CH~2~O), 2.46--2.50 (m, 1H, COCH~2~), 2.56--2.57 (m, 1H, COCH~2~CHN), 2.78--2.80 (m, 2H, COCH~2~, COCH~2~CHN), 3.29--3.33 (m, 1H, CH~2~O), 3.44--3.48 (m, 2H, CH~2~O), 3.55--3.56 (m, 1H, CH~2~O), 3.97--3.98 (m, 1H, CH~2~O), 4.30--4.36 (m, 2H, CH~2~N), 4.46--4.50 (m, 1H, CH), 4.48--4.52 (m, 1H, CHN), 6.98--7.73 (m, 10H, ArH), 11.78 (br, 1H, NH); ^13^C NMR (125 MHz, CDCl~3~): δ = 15.1, 15.2, 37.5, 41.1, 43.9, 49.5, 56.7, 56.9, 57.4, 59.5, 96.0, 111.5, 126.4, 126.6, 128.0, 128.2, 129.0, 129.2, 135.2, 136.8, 159.8, 207.3; HRMS (EI^+^): *m*/*z* calcd for C~26~H~32~N~3~O~5~ \[M + H\]^+^, 466.2336; found, 466.2341.

### (1*R*,5*R*)-2-(4-Methoxybenzyl)-3-((4-methoxybenzyl)amino)-4-nitro-2-azaspiro\[bicyclo\[3.3.1\]nonane-9,2′-\[1,3\]dioxolan\]-3-en-7-one (**4o**) {#sec4-3-15}

Yellow solid; mp 164.1 °C; IR (KBr): 3417, 1719, 1614, 1547, 1355, 1276, 1028, 712 cm^--1^; ^1^H NMR (400 MHz, DMSO-*d*~6~): δ = 2.50--2.62 (m, 2H, COCH~2~, COCH~2~CH), 2.85--2.93 (m, 2H, COCH~2~, COCH~2~CH), 3.38--3.42 (m, 1H, CH~2~O), 3.54--3.58 (m, 1H, CH~2~O), 3.74 (s, 3H, OCH~3~), 3.76 (s, 3H, OCH~3~), 4.00--4.11 (m, 3H, CH~2~O, CH~2~N), 4.42--4.43 (m, 2H, CH~2~N), 4.62--4.76 (s, 2H, CH, CHN), 6.90--6.92 (m, 2H, ArH), 6.98--7.00 (m, 2H, ArH), 7.10--7.12 (m, 2H, ArH), 7.30--7.32 (m, 2H, ArH), 11.8 (br, 1H, NH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 40.6, 40.8, 42.1, 49.4, 55.4, 55.6, 56.4, 59.7, 65.4, 65.7, 103.4, 111.1, 114.7, 114.7, 128.0, 128.9, 129.1, 129.7, 158.7, 159.3, 159.3, 207.0; HRMS (EI^+^): *m*/*z* calcd for C~26~H~30~N~3~O~7~ \[M + H\]^+^, 496.2078; found, 496.2078.

### (5*R*,9*R*)-10-Benzoyl-11,11-dimethoxy-2,3,5,6,8,9-hexahydro-7*H*-5,9-methanooxazolo\[3,2-*a*\]azocin-7-one (**6a**) {#sec4-3-16}

Yellow liquid; IR (KBr): 3415, 2959, 1714, 1528, 1405, 1285, 1113, 1070, 745 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.54--2.57 (m, 2H, COCH~2~), 2.76--2.80 (m, 1H, COCH~2~CHN), 2.87--2.91 (m, 1H, COCH~2~CHN), 3.30 (s, 3H, CH~3~O), 3.39--3.41 (m, 1H, CH), 3.44 (s, 3H, CH~3~O), 3.55--3.60 (m, 1H, CHN), 3.83--3.87 (m, 2H, CH~2~N), 4.16--4.23 (m, 2H, CH~2~O), 7.27--7.32 (m, 3H, ArH), 7.36--7.38 (m, 2H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 34.6, 42.6, 44.7, 46.6, 49.0, 49.0, 55.7, 67.6, 87.4, 97.9, 127.3, 127.5, 129.0, 143.2, 162.1, 190.0, 209.2; HRMS (EI^+^): *m*/*z* calcd for C~19~H~22~NO~5~ \[M + H\]^+^, 344.1492; found, 344.1488.

### (5*R*,9*R*)-10-Benzoyl-11,11-diethoxy-2,3,5,6,8,9-hexahydro-7*H*-5,9-methanooxazolo\[3,2-*a*\]azocin-7-one (**6b**) {#sec4-3-17}

Yellow solid; mp 199.4 °C; IR (KBr): 3416, 2974, 1719, 1542, 1454, 1226, 1116, 1070, 745 cm^--1^; ^1^H NMR (500 MHz, DMSO-*d*~6~): δ = 1.12--1.15 (m, 3H, C~3~CH~2~O), 1.23--1.26 (m, 3H, C~3~CH~2~O), 2.20--2.23 (m, 1H, COCH~2~), 2.52--2.55 (m, 1H, COCH~2~), 2.74--2.82 (m, 2H, COCH~2~CHN), 3.41--3.45 (m, 1H, CH), 3.48--3.57 (m, 3H, CH~2~N, C~3~CH~2~O), 3.62--3.70 (m, 3H, C~3~CH~2~O), 3.09--4.13 (m, 1H, CHN), 4.18--4.23 (m, 2H, CH~2~O), 7.20--7.22 (m, 2H, ArH), 7.27--7.34 (m, 3H, ArH); ^13^C NMR (125 MHz, DMSO-*d*~6~): δ = 15.7, 15.8, 35.7, 42.8, 45.1, 46.3, 55.4, 56.6, 56.9, 68.4, 86.8, 97.9, 127.7, 127.7, 129.2, 144.0, 162.3, 188.3, 209.4; HRMS (EI^+^): *m*/*z* calcd for C~21~H~26~NO~5~ \[M + H\]^+^, 372.1805; found, 372.1802.

### (5*R*,9*R*)-10-Benzoyl-11,11-dimethoxy-2,3,5,6,8,9-hexahydro-7*H*-5,9-methanothiazolo\[3,2-*a*\]azocin-7-one (**6c**) {#sec4-3-18}

Yellow liquid; IR (KBr): 3440, 2956, 1715, 1593, 1496, 1407, 1246, 1115, 1061, 750 cm^--1^; ^1^H NMR (500 MHz, CDCl~3~): δ = 2.20--2.23 (m, 1H, COCH~2~), 2.45--2.49 (m, 1H, COCH~2~), 2.58--2.64 (m, 2H, COCH~2~CHN), 2.92--2.98 (m, 2H, CH~2~S), 3.16 (s, 3H, OCH~3~), 3.25 (s, 3H, OCH~3~), 3.27--3.31 (m, 1H, CH), 3.46--3.49 (m, 1H, CH~2~N), 3.62--3.65 (m, 1H, CH~2~N), 3.79--3.83 (m, 1H, CHN), 7.24--7.29 (m, 5H, ArH); ^13^C NMR (125 MHz, CDCl~3~): δ = 27.9, 36.4, 41.7, 45.5, 48.8, 48.9, 53.0, 57.0, 97.5, 102.0, 126.4, 128.2, 129.0, 141.3, 161.3, 190.7, 208.4; HRMS (EI^+^): *m*/*z* calcd for C~19~H~22~NO~4~S \[M + H\]^+^, 360.1264; found, 360.1265.
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